Redesign Science is a New York–based computational drug discovery company that combines physics, computer science and biotechnology to advance new small molecule therapeutics. Its platform uses computational approaches to understand protein dynamics for precision structure-based drug discovery and to expand the druggable proteome. The company targets applications from precision cancer therapeutics to first-in-class small molecules for inflammatory bowel disease. Redesign Science is led by CEO David Rooklin and cofounder/CTO Haotian Li. The company plans to use new funding to expand its cloud computing infrastructure and to advance and scale core screening algorithms across diverse biological target classes. It raised $15M in Seed-2 and Seed-3 financing to support those efforts.

Total raised

$15M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2021